Prantesh Jain, MD
Medical Oncology · Buffalo, NYNPI 1710295019
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,650 of the $10,686 with a category attached, or 71.6%. 14 manufacturers reported payments, led by Amgen at 32.4% of the total. Reporting peaked in 2024 at $8,199 and has fallen 72.9% since, to $2,222 in 2025.
Across 25 payments — averaging $427.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- Catalyst Pharmaceuticals, Inc.$2K
- Boehringer Ingelheim$2K
- AstraZeneca$2K
- Johnson & Johnson$124
- Janssen Research & Development, LLC$98
- plus $280 from 8 others
Across 54 payments — averaging $14,051 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$680K
- Aadi Bioscience, Inc.$55K
- Deciphera Pharmaceuticals Inc.$19K
- E.r. Squibb & Sons, L.L.C.$3K
- Merck$1K
- Incyte Corporation$548
What the payments were for
- Consulting fees$7,65072%
- Speaking & faculty fees$2,25021%
- Food & beverage$7467%
- Education$400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 4 | $3,462 |
| Catalyst Pharmaceuticals, Inc. | 2 | $2,350 |
| Boehringer Ingelheim | 1 | $2,220 |
| AstraZeneca(2 entities) | 5 | $2,152 |
| Johnson & Johnson | 1 | $124 |
| Janssen Research & Development, LLC | 1 | $98 |
| Incyte Corporation | 3 | $54 |
| Merck | 2 | $53 |
| Exelixis Inc. | 1 | $44 |
| Deciphera Pharmaceuticals Inc. | 1 | $43 |
| EMD Serono, Inc. | 1 | $40 |
| Taiho Oncology, Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,686 in reported general payments places this provider in the 55th percentile of 498 medical oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TepmetkoTepotinib Hcl | 20 | $376,401 |
| TagrissoOsimertinib Mesylate | 22 | $345,438 |
| Prochlorperazine Maleate | 16 | $333 |
| Dexamethasone | 20 | $322 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| EMD Serono, Inc.Tepmetko | $40 | $376,40120 claims |
| AstraZenecaTagrisso | $2,152 | $345,43822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 498 medical oncology providers in New York.
Other medical oncology in Buffalo
- Ehsan MalekBuffalo$826K
- Marco DavilaBuffalo$437K
- Saby GeorgeBuffalo$234K
- Nikhil KhushalaniBuffalo$193K
- Francisco Hernandez IlizaliturriBuffalo$158K
- Craig ThompsonNew York$4.8M
- Andrew SeidmanNew York$1.3M
- Maria TheodoulouAlbany$1.1M
- Joshua RichterNew York$971K
- Edward GelmannNew York$944K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.